LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research note issued to investors on Friday.

Other analysts have also issued reports about the company. Mizuho dropped their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Robert W. Baird increased their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Stock Up 0.1 %

LivaNova stock opened at $47.68 on Friday. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of 113.52 and a beta of 1.00. LivaNova has a 52 week low of $43.15 and a 52 week high of $64.47. The business’s 50-day moving average price is $48.30 and its 200 day moving average price is $49.56. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after acquiring an additional 265,291 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in shares of LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after purchasing an additional 806,374 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of LivaNova by 19.1% in the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock valued at $74,690,000 after purchasing an additional 258,730 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after purchasing an additional 8,331 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of LivaNova by 8.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock valued at $60,710,000 after purchasing an additional 107,693 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.